New drug trial aims to slow devastating ALS progression
NCT ID NCT07174492
Summary
This study is testing whether adding an oral drug called masitinib to the standard ALS medication (riluzole) can better slow the disease and improve daily function. It will involve 412 adults with ALS who are already taking riluzole. Participants will be randomly assigned to receive either masitinib or a placebo pill, in addition to their standard care, for 48 weeks to see which group does better.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS (ALS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Aiginition Hospital
Athens, Greece
Contact
Conditions
Explore the condition pages connected to this study.